Great Lakes Advisors LLC Sells 2,698 Shares of Integer Holdings Co. (NYSE:ITGR)

Great Lakes Advisors LLC lessened its stake in Integer Holdings Co. (NYSE:ITGR - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,213 shares of the medical equipment provider's stock after selling 2,698 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.12% of Integer worth $5,462,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Integer during the fourth quarter worth $38,073,000. Eagle Asset Management Inc. bought a new stake in shares of Integer in the 3rd quarter valued at about $14,403,000. Laurus Investment Counsel Inc. acquired a new stake in Integer in the 4th quarter valued at about $5,422,000. New York State Common Retirement Fund grew its holdings in Integer by 20.9% during the fourth quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider's stock worth $30,820,000 after purchasing an additional 40,158 shares during the period. Finally, Bamco Inc. NY increased its position in Integer by 17.4% during the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider's stock worth $33,069,000 after buying an additional 37,700 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ITGR shares. Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Wells Fargo & Company reaffirmed an "overweight" rating and set a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Truist Financial upped their price objective on shares of Integer from $147.00 to $163.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. KeyCorp raised their target price on shares of Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, Benchmark upped their price target on shares of Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $149.00.

Remove Ads

Integer Stock Performance

Shares of ITGR stock traded up $1.36 on Monday, hitting $119.25. The company's stock had a trading volume of 549,399 shares, compared to its average volume of 373,080. Integer Holdings Co. has a fifty-two week low of $107.11 and a fifty-two week high of $146.36. The company has a market capitalization of $4.01 billion, a PE ratio of 35.49, a PEG ratio of 1.72 and a beta of 1.24. The stock's 50 day moving average is $134.11 and its 200-day moving average is $132.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95.

Integer (NYSE:ITGR - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Equities research analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.